 |
Huperzine A, a novel promising
acetylcholinesterase inhibitor.
Learning and Memory
Cheng, Dong Hang 1; Ren, Hua 1; Tang, Xi Can 1,2
Neuroreport. 8(1):97-101, December
20, 1996.
Abstract:
THE effects of huperzine A on memory impairments induced by
scopolamine were evaluted using a radial maze task and inhibition of
cholinesterase in vitro compared with the effects of E2020 and
tacrine. Scopolamine (0.2 mg kg-1) significantly impaired spatial
memory in rats. Huperzine A (0.1-0.4 mg kg-1, p.o.), E2020 (0.5-1.0
mg kg-1, p.o.) and tacrine (1.0-2.0 mg kg-1, p.o) could reverse
these scopolamine-induced memory deficits. The ratios of huperzine
A, E2020 and tacrine for butyrylcholinesterase:acetylcholinesterase
determined by a colourimetric method were 884.57, 489.05, and 0.80,
respectively. The results demonstrated that huperzine A was the most
selective acetylcholinterase inhibitor, and improved the working
memory deficit induced by scopolamine significantly better than did
E2020 or tacrine, suggesting it may be a promising agent for
clinical therapy of cognitive impairment in patients with
Alzheimer's Disease.
(C) Lippincott-Raven Publishers.
|
|
